Add Covid to the growing list of pathogenic candidates behind MS.
It's such a rare thing to see someone actually testing tissue, and brain tissue at that(!), for any neurological disease.
And profitable. Wouldn't want to ignore the Bayh-Doyle Act.
Remember when academic research had the feel of being above smear, above the mercenary? Some people feel that may have changed a little back in 1980 with Bayh-Doyle.
Part of me is appreciative of the implication in "post-acute", although it's effectively muted by "syndrome".
I'm curious, too, what sort of internal political dynamics might appear considering Yale's history in at least one area they'd be looking at. I hope they give Iwasaki free rein.
It buggers this bogged brain as to when and why medicine stopped assuming that when symptoms persist after acute stage, the pathogen was still mucking about somewhere in the patient.
Isn't the way of infections typically acute and treat (if treatable)? Then either the patient's infection...
Hmm...Strle was an author. He was also an author of a similar study more than a decade ago, one with Steere.
I am conflicted now. Is this another deflection? Focus on acute infections, maybe even a little disseminated, but decidedly no late stage? Do these more "dangerous" strains hold up as...
"To our knowledge, no large whole genome sequence (WGS) studies of human isolates have been conducted. Fewer than 50 human isolates analyzed by WGS have been publicly reported, either sporadically or included in cohorts consisting primarily of tick-derived isolates and in the majority of studies...
The study:
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011243
Findings as summarized in Time:
https://time.com/6310027/lyme-disease-genes-severe-disease/?
My summary:
How sick you get depends on the strain (vs species) of Lyme you're infected with. It's not a...
Late 60's through the early 80's was a very strange stretch, with some very peculiar and disabling diseases emerging. Certainly not keepsake days for the likes of the CDC and NHS.
Makes one wonder what kind of water was going into what kind of cool aid.
Blunting immune responses theoretically can bring its own set of problems if there is an active - or reactivated - pathogen involved. This seems particularly relevant to LC if Covid persists in privileged sites, but also for lots of other things including ME/CFS and other neurological disorders...
I don't recall what UK is using these days. It used to be the C6. That's arguably worth a shot if you're covered for it.
The US also used to use the C6. It was being positiioned to replace the 2T I think. But that didn't happen. Now there are the MTTT's, of which I think there are 4 different...
@Ash , yes it can and has.
But that's a loaded topic on many levels. One of those is that Bb has been sometimes, albeit rarely, found in synovial fluid after treatment (rarely cultured even without treatment). Even when it's not cultured, many suspect Bb persisters are behind...
Author lists reads like a Who's Who at the IDSA Lyme school. Makes sense it would since they're revisiting the arthritis white whale.
They can propose all they like. Wish they'd move away from the arthritis obsession, though. That it's - by some - felt to be a forced fit perhaps attributed to...
:(
I would suggest the way forward and out from this is the development of readily available diagnostics that will unequivocally confirm or disprove active infection.
Anything less has time and time again proven to destroy lives - irrespective of how one perceives Lyme.
Sometimes I wish researchers and advocates would be more careful with wording, as well intentioned as they may be. It can have a misleading effect. There are no generally effective therapies and few are really looking, current scientific findings are all over the place, and clinical experience...
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.